IOL Chemicals & Pharmaceuticals
- Market Cap
- ₹5,611 Cr
- P/E
- 27.58
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 11.30%
- Debt to Equity
- 0.10
- EPS (TTM)
- ₹6.93
- Book Value
- ₹65.62
- Market Cap
- ₹5,611 Cr
- P/E (TTM)
- 27.58
- P/B
- 2.91
- ROE
- 8.42%
- Dividend Yield
- 0.52%
- EBITDA
- ₹290 Cr
- 52W High
- ₹224.00
- 52W Low
- ₹67.19
- Day Range
- ₹190.61 – ₹196.33
- Volume
- 8,94,054
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,878.90 | 41.11 | 4,50,811 | 5.05 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,141.50 | 87.95 | 2,95,772 | 16.43 | 0.26% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,645.10 | 77.06 | 1,76,685 | 9.62 | 0.81% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,327.30 | 93.84 | 1,25,747 | 20.75 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,204.70 | 28.74 | 1,20,169 | 4.32 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,379.80 | 41.13 | 1,15,169 | 2.97 | 0.58% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,389.30 | 38.73 | 1,12,236 | 3.17 | 0.93% | 11.60% | 15.50% | 28,139 | 2,855 | |
| 191.16 | 27.58 | 5,611 | 2.91 | 0.50% | 8.42% | 11.30% | 2,751 | 203 | |
| Median 8 companies | 1,634.10 | 41.12 | 1,22,958 | 4.69 | 0.54% | 16.25% | 16.65% | 22,770 | 2,808 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 48
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 72
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 74
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 61
- Good
- Solvency, leverage, coverage 9% weight
- Momentum
- 86
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 64
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 22.1%
Weaknesses
3- Stock is trading at 2.95 times its book value
- The company has delivered a poor sales growth of 3.35% over past five years.
- Company has a low return on equity of 7.74% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 7 | 10 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Strong Bullish | 2 | 0 | 8 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 51.39
- Neutral
- MACD (12,26,9)
- 2.28
- Bullish
- SMA (50)
- 195.33
- Bearish
- SMA (200)
- 135.48
- Bullish
As of
Analyst Rating
1 of 1 analyst rates Buy, 0 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +14.86% |
|---|---|
| 5Y | +3.35% |
| 3Y | +1.51% |
| 1Y | +11.54% |
| TTM | +26.67% |
Net profit
| 10Y | Turned to profit |
|---|---|
| 5Y | −20.88% |
| 3Y | −0.48% |
| 1Y | +36.63% |
| TTM | +73.50% |
Operating cash flow
| 10Y | +28.09% |
|---|---|
| 5Y | −10.85% |
| 3Y | +20.27% |
| 1Y | +19.55% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +2.85 pp |
|---|---|
| 5Y | −18.46 pp |
| 3Y | +1.40 pp |
| 1Y | +1.92 pp |
| TTM | +2.65 pp |
Revenue by year
| Mar 2017 | ₹711 Cr |
|---|---|
| Mar 2018 | ₹983 Cr |
| Mar 2019 | ₹1,685 Cr |
| Mar 2020 | ₹1,894 Cr |
| Mar 2021 | ₹1,967 Cr |
| Mar 2022 | ₹2,184 Cr |
| Mar 2023 | ₹2,217 Cr |
| Mar 2024 | ₹2,133 Cr |
| Mar 2025 | ₹2,079 Cr |
| Mar 2026 | ₹2,319 Cr |
Net profit by year
| Mar 2017 | ₹5.00 Cr |
|---|---|
| Mar 2018 | ₹28.00 Cr |
| Mar 2019 | ₹237 Cr |
| Mar 2020 | ₹361 Cr |
| Mar 2021 | ₹445 Cr |
| Mar 2022 | ₹166 Cr |
| Mar 2023 | ₹140 Cr |
| Mar 2024 | ₹135 Cr |
| Mar 2025 | ₹101 Cr |
| Mar 2026 | ₹138 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
IOL Chemicals & Pharmaceuticals trades at a market cap of ₹4,300 Cr with a PE of 30.5x and near-zero debt. The company has seen a sharp TTM profit recovery of 44% but carries a weak 5-year sales CAGR of just 3% and a subdued 3-year ROE of 8%.
- Company is almost debt-free, providing financial flexibility and lower interest burden
- TTM profit growth of 44% signals a meaningful earnings recovery after years of decline
- Promoter holding increased by 4.86% in the last quarter, indicating insider confidence
- Stock has delivered 53% returns over the past 1 year, reflecting strong momentum
- 10-year compounded profit growth of 19% demonstrates long-term earnings capability
- Healthy dividend payout of 22.1% shows commitment to returning capital to shareholders
- 10-year sales CAGR of 15% indicates the company scaled well over the longer term
- TTM sales growth of 12% suggests demand recovery after a sluggish 3-year period
- 5-year compounded profit growth is -20%, indicating a prolonged earnings downcycle
- 5-year sales CAGR of only 3% reflects persistently weak topline growth
- 3-year ROE of just 8% is well below what quality pharma/chemical companies typically deliver
- PE of 30.5x is expensive relative to the low single-digit 3-year sales CAGR of 2%
- 3-year compounded profit growth of only 1% shows the recovery is very recent and unproven
- Last year ROE of 8% and 3-year ROE of 8% show no improvement in capital efficiency
- 5-year stock CAGR of just 2% suggests the market rewarded shareholders poorly over a medium-term horizon
- Dividend yield of 0.7% offers limited income cushion at current valuations
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: IOL Chemicals experienced a contained fire incident at one manufacturing unit with minimal impact—no injuries, no major property damage, and a short 8–10 day suspension limited to a single unit. The event is operationally insignificant given normal functioning across remaining facilities, and the outlook remains unchanged pending restoration completion.
- Minor fire at Minoxidil unit Jun 11
A minor fire at Unit-9B in Barnala on June 9, 2026 has suspended Minoxidil operations for 8–10 days. No injuries or significant property damage reported; all other units operating normally.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 | 795 |
| Expenses | 481 | 476 | 454 | 452 | 484 | 476 | 465 | 490 | 510 | 523 | 527 | 653 | 686 |
| Operating Profit | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 | 57 | 57 | 93 | 104 | 109 |
| OPM % | 12% | 9% | 10% | 10% | 8% | 9% | 12% | 11% | 10% | 10% | 15% | 14% | 14% |
| Other Income | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 | 7 | −6 | 2 | 8 | 5.51 |
| Interest | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 4 | 5.44 |
| Depreciation | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 20 | 20 | 21 | 22.19 |
| PBT | 51 | 32 | 38 | 39 | 26 | 28 | 45 | 46 | 41 | 28 | 71 | 87 | 87.25 |
| Tax % | 26% | 28% | 25% | 24% | 26% | 26% | 30% | 25% | 26% | 25% | 25% | 26% | 25% |
| Net Profit | 38 | 23 | 28 | 30 | 19 | 21 | 32 | 34 | 30 | 21 | 53 | 64 | 65.03 |
| EPS (₹) | 1.29 | 0.79 | 0.96 | 1.01 | 0.65 | 0.70 | 1.08 | 1.16 | 1.02 | 0.70 | 1.81 | 2.20 | 2.22 |
| YoY Sales growth | 1 | −1 | −14 | −11 | −4 | 1 | 5 | 10 | 8 | 11 | 17 | 37 | 40 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 385 | 580 | 711 | 983 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | 2,133 | 2,079 | 2,319 | 2,751 |
| Expenses | 373 | 529 | 608 | 863 | 1,276 | 1,321 | 1,375 | 1,927 | 1,990 | 1,901 | 1,877 | 2,049 | 2,388 |
| Operating Profit | 11 | 51 | 102 | 120 | 410 | 574 | 592 | 257 | 227 | 232 | 202 | 270 | 363 |
| OPM % | 2.9% | 9% | 14% | 12% | 24% | 30% | 30% | 12% | 10% | 11% | 10% | 12% | 13% |
| Other Income | 1 | 1 | 1 | 6 | 10 | 16 | 24 | 17 | 25 | 30 | 22 | 9 | 10 |
| Interest | 59 | 61 | 68 | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 15 | 15 | 16 |
| Depreciation | 29 | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 72 | 80 | 84 |
| PBT | −75 | −39 | 6 | 31 | 336 | 533 | 571 | 223 | 189 | 183 | 138 | 184 | 272 |
| Tax % | −12% | 4% | 21% | 12% | 30% | 32% | 22% | 26% | 26% | 26% | 27% | 25% | — |
| Net Profit | −67 | −40 | 5 | 28 | 237 | 361 | 445 | 166 | 140 | 135 | 101 | 138 | 203 |
| EPS (₹) | −2.80 | −1.42 | 0.17 | 0.99 | 8.32 | 12.70 | 15.15 | 5.64 | 4.77 | 4.61 | 3.44 | 4.69 | 6.93 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 5% | 8% | 14% | 17% | 22% | 23% | 21% | — |
| Sales growth | −32 | 51 | 22 | 38 | 71 | 12 | 4 | 11 | 2 | −4 | −3 | 12 | 27 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 56 | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves | 160 | 129 | 132 | 160 | 417 | 757 | 1,202 | 1,332 | 1,448 | 1,553 | 1,629 | 1,740 | 1,867 |
| Borrowings | 400 | 453 | 447 | 422 | 284 | 59 | 3 | 44 | 80 | 33 | 117 | 135 | 201 |
| Other Liabilities | 94 | 135 | 182 | 214 | 184 | 297 | 347 | 526 | 434 | 600 | 577 | 653 | 704 |
| Total Liabilities | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,587 | 2,830 |
| Fixed Assets | 403 | 400 | 374 | 406 | 412 | 469 | 512 | 561 | 751 | 933 | 1,170 | 1,181 | 1,191 |
| CWIP | 4 | 4 | 21 | 7 | 27 | 19 | 48 | 105 | 90 | 101 | 22 | 96 | 189 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 20 | 21 | 21 | 21 | 21 |
| Other Assets | 295 | 369 | 422 | 439 | 503 | 682 | 1,048 | 1,292 | 1,159 | 1,190 | 1,168 | 1,289 | 1,429 |
| Total Assets | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,587 | 2,830 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | −47 | 18 | 83 | 120 | 273 | 471 | 380 | 91 | 123 | 290 | 179 | 214 |
| Investing | −5 | −27 | −23 | −50 | −63 | −184 | −317 | −121 | −119 | −191 | −154 | −198 |
| Financing | 50 | 9 | −60 | −70 | −197 | −272 | −58 | −2 | −4 | −92 | 46 | −29 |
| Net Cash Flow | −2 | 0 | 1 | −1 | 13 | 15 | 4 | −31 | 0 | 7 | 70 | −13 |
| Free Cash Flow | −53 | −9 | 61 | 71 | 213 | 391 | 272 | −60 | −86 | 18 | −34 | 44 |
| CFO/EBITDA | −413 | 34 | 82 | 105 | 83 | 102 | 88 | 60 | 75 | 144 | 97 | 93 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 31 | 55 | 58 | 54 | 43 | 52 | 56 | 79 | 83 | 81 | 90 | 95 |
| Inventory Days | 279 | 201 | 201 | 109 | 66 | 64 | 98 | 95 | 77 | 111 | 95 | 91 |
| Days Payable | 92 | 102 | 115 | 83 | 42 | 62 | 79 | 95 | 74 | 123 | 112 | 118 |
| Cash Conversion Cycle | 218 | 154 | 144 | 80 | 67 | 55 | 74 | 79 | 86 | 69 | 73 | 68 |
| Working Capital Days | 59 | 39 | 36 | 23 | 43 | 46 | 66 | 71 | 72 | 71 | 58 | 53 |
| ROCE % | −3% | 4% | 12% | 15% | 56% | 68% | 54% | 18% | 14% | 12% | 9% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view IOL Chemicals & Pharmaceuticals insights
76 extracted metrics across FY07–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q2 FY27 concall · Sep 2026Transcript Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026Transcript PPT
- 6 Jul 2026
- 4 Jul 2025
- 5 Nov 2024
- 28 Jun 2024
- 30 Jun 2023
Frequently Asked Questions about IOL Chemicals & Pharmaceuticals
What does IOL Chemicals & Pharmaceuticals Ltd do?
Where is IOL Chemicals & Pharmaceuticals Ltd (IOLCP) listed?
Which sector does IOL Chemicals & Pharmaceuticals Ltd belong to?
What is the market capitalisation of IOL Chemicals & Pharmaceuticals Ltd?
What is the PE ratio of IOL Chemicals & Pharmaceuticals Ltd?
What is the 52-week high and low of IOL Chemicals & Pharmaceuticals Ltd?
Does IOL Chemicals & Pharmaceuticals Ltd pay dividends?
What is the Return on Equity (ROE) of IOL Chemicals & Pharmaceuticals Ltd?
Company Information
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market. It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/IOLCP.md for IOL Chemicals & Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.